Nasdaq · Biotech stocks database

ABVX — Abivax SA

ABVX (Abivax SA) stock: $85.73, $7.48B market cap, $581.4M cash, $6.90B EV, $8.18B fully diluted market cap. Lead program: ABX464 (Ulcerative Colitis), Phase 3. Data from Fully Diluted's biotech stocks database.

What they do

We are a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. We focus on indications where existing treatments have left patients with significant unmet needs, and where we believe our investigational agents have the potential to be meaningfully differentiated from currently available therapies.

Source: 20-F FY2025 via SEC EDGAR

Share price

$85.73

Market cap

$7,480.3M

Cash

$581.4M

Enterprise value

$6,898.9M

Balance sheet

Cash	$581.4M
Debt	$0.0M
Net cash	$581.4M
Enterprise value	$6,898.9M
Basic shares	79.2M shares
Fully diluted shares	95.4M shares
Fully diluted market cap	$8,182.9M
Cash per share	$7.34

Cash figures as of 2025-12-31. Database snapshot: 2026-11-07.

Share structure

Common

87.2M

Pre-funded warrants

0.0M

Options

0.0M

RSUs

7.8M

Warrants

0.5M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

—

FDSO

95.4M

Cap table as of 2026-07-06.

Price history

Loading ABVX daily closes…

Loading price history…

Next catalyst

Obefazimod 50 mg Capsule · Now - Nov 24, 2026 Now · Phase 1 · Healthy

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Now - Nov 24, 2026 Now	Obefazimod 50 mg Capsule	Phase 1	Healthy	—
GUIDEDDec 1-31 in 24d	obefazimod NDA submission to FDA in ulcerative colitis	Not disclosed	ulcerative colitis	late Q4 2026
Jan 12 - Feb 23 in 9 wks	Obefazimod	Phase 2	Moderately to Severely Active Crohn Disease	mid-year 2027 Est. Jul 16, 2027 · guidance midpoint
Apr 12 - May 24 in 17 mo	ABX464	Phase 2	Ulcerative Colitis	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Lead drug	ABX464
Lead indication	Ulcerative Colitis
Lead phase	Phase 3
Active trials	5

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT05535946	Phase 3	Active, not recruiting	Sponsor	ABVX	—	Ulcerative Colitis	—
NCT06456593	Phase 2	Recruiting	Sponsor	ABVX	—	Moderately to Severely Active Crohn Disease	mid-year 2027 Est. Jul 16, 2027 · guidance midpoint
NCT05177835	Phase 2	Active, not recruiting	Sponsor	ABVX	—	Ulcerative Colitis	—
NCT03897543	Phase 2	Recruiting	Sponsor	ABVX	—	Carcinoma, Hepatocellular	—
NCT07453784	Phase 1	Recruiting	Sponsor	ABVX	—	Healthy	—

Sponsor-matched active trials from ClinicalTrials.gov (5 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 5 active trials for Abivax S.A. on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
ADAR1 Capital Management	1,804,703	+410,684	11.30%	2026-08-14
RA Capital Management	1,132,557	+1,132,557	1.31%	2026-08-14
Logos Global Management	1,024,000	+349,000	5.87%	2026-08-14
Cormorant Asset Management	675,000	-85,000	4.61%	2026-08-14
Boxer Capital	605,000	+405,000	6.07%	2026-08-14
OrbiMed Advisors	546,522	+80,822	1.38%	2026-08-14
Vivo Capital	414,899	+175,360	5.05%	2026-08-14
Ikarian Capital	328,635	+271,000	7.10%	2026-08-14
Great Point Partners	204,314	+204,314	6.41%	2026-08-14
Perceptive Advisors	74,000	-254,884	0.15%	2026-08-14
RTW Investments	26,400	+26,400	0.03%	2026-08-14
Baker Bros. Advisors	0	-875,796	0.00%	2026-08-14
Ally Bridge Group	0	-33,712	0.00%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Get the weekly biotech catalyst rundown.
Cash runways, financings, and trial readouts for all 721 stocks.

Subscribe to Compounding Ego

ABVX — Abivax SA

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

ABVX — Abivax SA ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

ABVX — Abivax SA